Eupraxia Pharmaceuticals Inc.
EPRX.TO
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 72.72% | 46.08% | 130.45% | 10.88% | 18.75% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 119.06% | 123.98% | 116.03% | 9.72% | 26.07% |
| Operating Income | -119.06% | -123.98% | -116.03% | -9.72% | -26.07% |
| Income Before Tax | -65.44% | -86.87% | -121.90% | -6.32% | -44.05% |
| Income Tax Expenses | 442.86% | 396.43% | 527.78% | -- | 212.00% |
| Earnings from Continuing Operations | -65.68% | -87.00% | -121.99% | -6.31% | -44.26% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -4.41% | -70.21% | -56.84% | -83.33% | -88.01% |
| Net Income | -65.74% | -87.11% | -122.55% | -7.03% | -45.51% |
| EBIT | -119.06% | -123.98% | -116.03% | -9.72% | -26.07% |
| EBITDA | -119.06% | -124.04% | -116.46% | -9.45% | -25.98% |
| EPS Basic | 12.82% | -13.00% | -51.80% | -13.79% | -54.98% |
| Normalized Basic EPS | 10.26% | -17.75% | -54.68% | -3.66% | -44.62% |
| EPS Diluted | 12.82% | -13.00% | -51.80% | -13.79% | -54.98% |
| Normalized Diluted EPS | 10.26% | -17.75% | -54.68% | -3.66% | -44.62% |
| Average Basic Shares Outstanding | 84.40% | 58.92% | 43.93% | 3.63% | 0.81% |
| Average Diluted Shares Outstanding | 84.40% | 58.92% | 43.93% | 3.63% | 0.81% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |